RESUMO
OBJECTIVES: There are no real-world data describing infection morbidity in relapsed/refractory myeloma (RRMM) patients treated with anti-CD38 isatuximab in combination with pomalidomide and dexamethasone (IsaPomDex). In this UK-wide retrospective study, we set out to evaluate infections experienced by routine care patients who received this novel therapy across 24 cancer centres during the COVID-19 pandemic. METHODS: The primary endpoint was infection morbidity (incidence, grading, hospitalization) as well as infection-related deaths. Secondary outcomes were clinical predictors of increased incidence of any grade (G2-5) and high grade (≥G3) infections. RESULTS: In a total cohort of 107 patients who received a median (IQR) of 4 cycles (2-8), 23.4% of patients experienced ≥1 any grade (G2-5) infections (total of 31 episodes) and 18.7% of patients experienced ≥1 high grade (≥G3) infections (total of 22 episodes). Median time (IQR) from start of therapy to first episode was 29 days (16-75). Six patients experienced COVID-19 infection, of whom 5 were not vaccinated and 1 was fully vaccinated. The cumulative duration of infection-related hospitalizations was 159 days. The multivariate (MVA) Poisson Regression analysis demonstrated that a higher co-morbidity burden with Charlson Co-morbidity Index (CCI) score ≥4 (incidence rate ratio (IRR) = 3, p = 0.012) and sub-optimal myeloma response less than a partial response (Assuntos
Tratamento Farmacológico da COVID-19
, COVID-19
, Mieloma Múltiplo
, Idoso
, Anticorpos Monoclonais Humanizados
, Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
, COVID-19/epidemiologia
, Dexametasona
, Humanos
, Mieloma Múltiplo/tratamento farmacológico
, Mieloma Múltiplo/etiologia
, Recidiva Local de Neoplasia/tratamento farmacológico
, Pandemias
, Estudos Retrospectivos
, Talidomida/análogos & derivados
, Reino Unido/epidemiologia